SCHEDULE: Soleus Capital Discloses 4.7% Stake in UroGen Pharma

Soleus Capital Master Fund and related entities have disclosed a 4.7% beneficial ownership stake in UroGen Pharma Ltd., holding 2,185,000 ordinary shares.

Summary

• Soleus Capital Master Fund, L.P. and its affiliated entities, including Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, collectively reported beneficial ownership of 2,185,000 ordinary shares of UroGen Pharma Ltd.
• This ownership represents 4.7% of UroGen Pharma Ltd.'s outstanding ordinary shares.
• The percentage is calculated based on 46,107,451 ordinary shares outstanding as of May 5, 2025, as reported in UroGen Pharma Ltd.'s Quarterly Report on Form 10-Q filed on May 12, 2025.
• The reporting persons hold shared voting and dispositive power over all 2,185,000 shares, with no sole voting or dispositive power.
• The shares were not acquired or held for the purpose of changing or influencing the control of UroGen Pharma Ltd.

Sentiment

Score: 5

Explanation: This is a neutral, factual disclosure of beneficial ownership, not indicating positive or negative performance or strategic shifts.

Stakeholder Impact

• Shareholders: The disclosure of a significant, though passive, stake by an investment fund may be viewed as a vote of confidence in the company's long-term prospects by some investors.

Key Dates

Keywords

UroGen Pharma, Soleus Capital, SEC Filing, Schedule 13G, Beneficial Ownership, UGN, Biotechnology, Pharmaceuticals, Investment Fund